Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Les Pavillons sous Bois, France Clinical Trials

A listing of Les Pavillons sous Bois, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (41) clinical trials

A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

The purpose of this study is to evaluate the pharmacokinetics (PK) of ustekinumab in subjects from 2 through less than (<) 18 years old in the USA, or 6 through less than (<) 18 years old in other countries and determine if it is similar to that observed in adults ...

Phase

5.49 miles

Learn More »

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with relapsed or refractory malignancies.

Phase

5.49 miles

Learn More »

SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias

Cerebellar ataxias (CA) and spastic paraplegias (SP) are genetically and clinically very heterogeneous. More than 40 loci are already known but the number of phenotypes is even greater suggesting further genetic heterogeneity. These progressive disorders are often severe and fatal, due to the absence of specific therapy. The SPATAX network ...

Phase

6.51 miles

Learn More »

Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

The CL1-64315-001 study is a phase I, international, multicentre, open-label, non-randomised, non-comparative study. This study is designed in two parts: one part for dose escalation, one part for dose expansion.

Phase

6.51 miles

Learn More »

A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy

Expansion Phase of the study: Subjects must have relapsed/refractory RMS or a solid malignant tumor (Ewing sarcoma, hepatoblastoma, neuroblastoma and Wilms tumor).

Phase

6.51 miles

Learn More »

Multicenter Safety Trial Assessing an Innovative Tumor Molecular and Cellular Print Medical Device in Glioma

Diagnostic in cancerology keeps based on biopsy or exeresis tissues anatomopathologic analysis. Micro-invasive biopsy approaches reduces chirurgical aggressivity but also tissue amount The innovative Medical Device ProTool offers a micro-invasive biopsy approach in parallel with classical chirurgical proceeding. It allows to complete heterogeneity tumoral analysis and peri-tumoral tissue environment.

Phase

6.7 miles

Learn More »

A Study Evaluating Venetoclax in Combination With Azacitidine in Subjects With Treatment-Na ve Higher-Risk Myelodysplastic Syndromes (MDS)

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in subjects with treatment-nave higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.

Phase

6.86 miles

Learn More »

A Study to Evaluate the Safety Pharmacokinetics and Efficacy of Isatuximab in Patients With Multiple Myeloma

Study duration for an individual patient will include a screening period for inclusion of up to 3 weeks, the treatment period and, a follow up period. Treatment with SAR650984 (isatuximab) may continue until disease progression, unacceptable adverse event, or other reason for discontinuation. After study treatment discontinuation, an end of ...

Phase

6.86 miles

Learn More »

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with selected advanced tumors characterized by wild-type TP53.

Phase

6.86 miles

Learn More »

Study of LEE011 BYL719 and Letrozole in Advanced ER+ Breast Cancer

The purpose of this trial is to inform the future clinical development of the two investigational agents in ER+ breast cancer, LEE011 (CDK4/6 inhibitor) and BYL719 (PI3K-alpha inhibitor). This is a multi-center, open-label Phase Ib study. The Phase Ib dose escalation will estimate the MTD and/or RP2D for three regimens: ...

Phase

6.86 miles

Learn More »